Please login to the form below

Not currently logged in
Email:
Password:

Micreos appoints chief medical officer

Dr Johan Frieling brings experience from Bayer and Genzyme

Micreos Dr Johan FrielingDutch biotech company Micreos has appointed Dr Johan Frieling as its new chief scientific officer.

In his new role Dr Frieling will be responsible for overseeing Micreos' antibiotic alternative, Staphefekt, as it begins clinical trials.

Mark Offerhaus, founder and chief executive officer of Micreos, said: “Johan has successfully developed a number of biopharmaceutical products up to FDA and EMA approval.

“For us he is the ideal person to lead Staphefekt to market in the new indications.”

Dr Frieling has over 20 years of clinical development experience and has previously held senior positions at Bayer, Genzyme and Pharmasquire Consultancy.

He joins Micreos from LFB Biotechnologies where he served most recently as director of global clinical research, with responsibility for all development products at the company.

Dr Freiling said: “It's a great time to be joining Micreos … I look forward to sharing my knowledge and leading the clinical development of Staphefekt, ultimately helping a large cohort of patients across the globe.”

23rd March 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics